Ibset Tablet contains Ramosetron 5 mcg, a selective serotonin 5-HT3 receptor antagonist used primarily for the management of irritable bowel syndrome with diarrhea (IBS-D) and prevention of nausea and vomiting associated with chemotherapy. Ramosetron exerts its therapeutic effect by blocking 5-HT3 receptors located on the vagal nerve terminals and in the central nervous system, thereby reducing gastrointestinal motility and visceral hypersensitivity. This action helps alleviate symptoms such as abdominal pain, diarrhea, and urgency commonly experienced in IBS-D patients. Ibset Tablet is indicated for adult patients presenting with these symptoms and is typically administered orally as per physician’s prescription. The pharmacokinetic profile of Ramosetron ensures a rapid onset of action and a prolonged duration, contributing to sustained symptom relief. Common adverse effects may include constipation, headache, and dizziness; however, the medication is generally well tolerated when used as directed. Caution is advised in patients with a history of hypersensitivity to Ramosetron or other 5-HT3 antagonists. Ibset should be used with care in individuals with severe hepatic or renal impairment. It is essential to follow prescribed dosing regimens and consult healthcare professionals before initiating therapy to ensure safety and efficacy.